Matches in SemOpenAlex for { <https://semopenalex.org/work/W2981677950> ?p ?o ?g. }
Showing items 1 to 59 of
59
with 100 items per page.
- W2981677950 endingPage "S983" @default.
- W2981677950 startingPage "S983" @default.
- W2981677950 abstract "Non-small cell lung cancer (NSCLC) is a prevalent disease with high mortality and poor response to traditional cytotoxic therapy. Immune checkpoint inhibitors (ICI) approvals were the landmark in the last years for the treatment of lung cancer. With these treatments, many patients with advanced disease are starting to see durable responses and longer survival rates. Several factors like obesity has been previously investigated for its role in cancer and promoting tumor growth, at least partially by inducing a chronic inflammatory state, but it’s unclear how it links to immunotherapy, where inflammation has been linked to treatment response,” High Body mass index (BMI) might have a positive impact in the outcomes of patients who are taking PD-1 or PD-L1 inhibitors, according to a recent study. In this study, we aim to determine if the body mass index (BMI) is a prognostic factor in patients treated with immunotherapy We retrospectively evaluated the outcomes of 30 patients with NSCLC confirmed histology, aged 18 years or older, treated with anti PD-1/PD-L1 from 2016 to 2018. BMI was stratified unto 2 groups: 1) normal and under-weighted (BMI < 25 kg/ m2) and 2) over-weighted and obese (BMI ≥ 25 kg/ m2). Simple descriptive statistics were created for all covariates. After statistical analyses with Kruskal-Wallis equality-of-populations rank test were related to progression free survival (PFS). A total of 30 lung cancer patients were enrolled in this study, divided by gender as 10 female-patients (33,33%) and 20 masculine-patients (66,67%) The median age was 63 years (youngest 41-year-old and oldest 81 years old). According to histology 20 patients have adenocarcinoma (66,67 %) and 10 patients have squamous tumors (33,33%). Analyzing the mutational status, the majority was EGFR Wild type (WT). The majority of patients involved (43,33 %; 13 patients) were given immunotherapy in the third-line setting or beyond. More than half of patients had over-weighted and obese BMI (group 2 – 56,67% (n=17)). The median follow-up was 86 days (1 quartile 35 days and 3rd quartile 291 days (minimum 5 days, maximum 971 days). The median PFS in group 1 was 98 days (1 quartile 56 days and 3rd quartile 407 days (minimum 28 days, maximum 495 days) and in over-weighted and obese was 74 days (1quartil 26 days and 3rd quartile 127 days (minimum 5 days, maximum 971 days). There were no statistical differences in PFS (p= 0,249) between higher or lower BMI groups (group1 vs. group 2). In this single institution cohort, BMI hadn’t a significant effect on outcomes of patients with lung cancer receiving anti PD-1/PD-L1 agents. As a critic to this evaluation we have that is for now a small group of patients and we think it is important to maintain studies in this field as the number of patients under this therapy increases." @default.
- W2981677950 created "2019-11-01" @default.
- W2981677950 creator A5004481055 @default.
- W2981677950 creator A5013742163 @default.
- W2981677950 creator A5054977661 @default.
- W2981677950 creator A5090699142 @default.
- W2981677950 date "2019-10-01" @default.
- W2981677950 modified "2023-10-18" @default.
- W2981677950 title "EP1.04-39 Is Body Mass Index a Prognostic Factor in Patients with Lung Cancer Treated with Immunotherapy?" @default.
- W2981677950 doi "https://doi.org/10.1016/j.jtho.2019.08.2160" @default.
- W2981677950 hasPublicationYear "2019" @default.
- W2981677950 type Work @default.
- W2981677950 sameAs 2981677950 @default.
- W2981677950 citedByCount "0" @default.
- W2981677950 crossrefType "journal-article" @default.
- W2981677950 hasAuthorship W2981677950A5004481055 @default.
- W2981677950 hasAuthorship W2981677950A5013742163 @default.
- W2981677950 hasAuthorship W2981677950A5054977661 @default.
- W2981677950 hasAuthorship W2981677950A5090699142 @default.
- W2981677950 hasBestOaLocation W29816779501 @default.
- W2981677950 hasConcept C121608353 @default.
- W2981677950 hasConcept C126322002 @default.
- W2981677950 hasConcept C143998085 @default.
- W2981677950 hasConcept C2776256026 @default.
- W2981677950 hasConcept C2777701055 @default.
- W2981677950 hasConcept C2780221984 @default.
- W2981677950 hasConcept C50382708 @default.
- W2981677950 hasConcept C66339696 @default.
- W2981677950 hasConcept C71924100 @default.
- W2981677950 hasConceptScore W2981677950C121608353 @default.
- W2981677950 hasConceptScore W2981677950C126322002 @default.
- W2981677950 hasConceptScore W2981677950C143998085 @default.
- W2981677950 hasConceptScore W2981677950C2776256026 @default.
- W2981677950 hasConceptScore W2981677950C2777701055 @default.
- W2981677950 hasConceptScore W2981677950C2780221984 @default.
- W2981677950 hasConceptScore W2981677950C50382708 @default.
- W2981677950 hasConceptScore W2981677950C66339696 @default.
- W2981677950 hasConceptScore W2981677950C71924100 @default.
- W2981677950 hasIssue "10" @default.
- W2981677950 hasLocation W29816779501 @default.
- W2981677950 hasOpenAccess W2981677950 @default.
- W2981677950 hasPrimaryLocation W29816779501 @default.
- W2981677950 hasRelatedWork W2009226744 @default.
- W2981677950 hasRelatedWork W2786497694 @default.
- W2981677950 hasRelatedWork W3137670083 @default.
- W2981677950 hasRelatedWork W3166455070 @default.
- W2981677950 hasRelatedWork W3171615116 @default.
- W2981677950 hasRelatedWork W3215044659 @default.
- W2981677950 hasRelatedWork W3217115064 @default.
- W2981677950 hasRelatedWork W4283212020 @default.
- W2981677950 hasRelatedWork W4306969170 @default.
- W2981677950 hasRelatedWork W4315778713 @default.
- W2981677950 hasVolume "14" @default.
- W2981677950 isParatext "false" @default.
- W2981677950 isRetracted "false" @default.
- W2981677950 magId "2981677950" @default.
- W2981677950 workType "article" @default.